Physician profile
Andrew P Rees
NPI 1932174166
$3,925.07
in general payments reported to CMS, 2019-2025
29 companies · $594 in 2025
The $594 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $254 · 2021: $240 · 2022: $623 · 2023: $674 · 2024: $721 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,988.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $442.23 | 2019-2025 | |
| Amgen INC. | $428.93 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $427.45 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $365.90 | 2019-2025 | Lifevest |
| Pfizer INC. | $335.70 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $300.20 | 2023-2025 | Uptravi |
| E.R. Squibb & Sons, L.L.C. | $247.58 | 2019-2024 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $202.61 | 2019-2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.99 | 2020-2025 | Jardiance |
| Medtronic Vascular, INC. | $123.83 | 2019 | |
| Merck Sharp & Dohme LLC | $113.75 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $99.36 | 2022-2025 | |
| Baxter Healthcare | $85.04 | 2022-2025 | Hillrom - Carnation Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $82.04 | 2020-2025 | Wainua |
| Akcea Therapeutics, INC. | $55.03 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $52.37 | 2021-2024 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $50.40 | 2019 | |
| Cleerly, INC. | $50.24 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Astellas Pharma US INC | $48.71 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $35.67 | 2022 | |
| Abiomed | $34.02 | 2025 | |
| Grifols USA, LLC | $30.52 | 2022 | |
| Daiichi Sankyo INC. | $29.39 | 2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $26.52 | 2019-2024 | |
| Itamar Medical INC | $23.58 | 2023 | Watchpatone |
| Arbor Pharmaceuticals, INC. | $20.56 | 2022 | |
| Novo Nordisk INC | $16.50 | 2025 | Wegovy |
| Kiniksa Pharmaceuticals, LTD. | $15.98 | 2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $13.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Rees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.